{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T19:43:41Z","timestamp":1789587821596,"version":"build-2803163510"},"reference-count":77,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T00:00:00Z","timestamp":1753920000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T00:00:00Z","timestamp":1753920000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"DOI":"10.1186\/s12879-025-11295-6","type":"journal-article","created":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T08:29:44Z","timestamp":1753950584000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Pre-treatment loss to follow-up and associated factors among drug-resistant tuberculosis patients diagnosed in Wakiso district, central Uganda"],"prefix":"10.1186","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2618-4752","authenticated-orcid":false,"given":"James","family":"Arinaitwe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Muleme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Perez N.","family":"Ochanda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Nuwematsiko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samson","family":"Omongot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barnabas","family":"Bakamutumaho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Buregyeya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,31]]},"reference":[{"key":"11295_CR1","unstructured":"WHO. World Health Organisation, Global Tuberculosis Report, 2022 [Online]. 2022. Available: https:\/\/www.iom.int\/sites\/g\/files\/tmzbdl486\/files\/documents\/2023-03\/Global-TB-Report-2022.pdf. Accessed."},{"issue":"26","key":"11295_CR2","doi-asserted-by":"publisher","first-page":"553","DOI":"10.46234\/ccdcw2021.143","volume":"3","author":"Y Xia","year":"2021","unstructured":"Xia Y, Huang F, Chen H, Wang N, Du X, Chen W, et al. The impact of COVID-19 on tuberculosis patients\u2019 behavior of seeking medical care - China, 2020. China CDC Wkly. 2021;3(26):553\u20136.","journal-title":"China CDC Wkly"},{"key":"11295_CR3","unstructured":"WHO. World Health Organisation Global Tuberculosis Report 2020 [Online]. 2020. Available: https:\/\/iris.who.int\/bitstream\/handle\/10665\/336069\/9789240013131-eng.pdf?sequence=1. Accessed."},{"key":"11295_CR4","unstructured":"Jilani TN, Avula A, Zafar Gondal A, et al. Active Tuberculosis. [Updated 2023 Jan 26]. In: StatPearls [Internet]. Treasure Island: StatPearls Publishing; 2025. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK513246\/."},{"key":"11295_CR5","unstructured":"WHO. World Health Organisation; Global Tuberculosis Report, 2018 [Online]. Geneva: WHO; 2018. Available: https:\/\/iris.who.int\/bitstream\/handle\/10665\/274453\/9789241565646-eng.pdf?sequence=1. Accessed."},{"key":"11295_CR6","doi-asserted-by":"publisher","unstructured":"Arega B, Menbere F, Getachew Y. Prevalence of rifampicin resistant Mycobacterium tuberculosis among presumptive tuberculosis patients in selected governmental hospitals in Addis Ababa, Ethiopia. BMC Infect Dis. 2019;19(1):307. https:\/\/doi.org\/10.1186\/s12879-019-3943-1. PMID: 30947695; PMCID: PMC6449910.","DOI":"10.1186\/s12879-019-3943-1"},{"key":"11295_CR7","doi-asserted-by":"publisher","unstructured":"Masenga SK, Mubila H, Hamooya BM. Rifampicin resistance in mycobacterium tuberculosis patients using GeneXpert at Livingstone Central Hospital for the year 2015: a cross sectional explorative study. BMC Infect Dis. 2017;17:640.\u00a0https:\/\/doi.org\/10.1186\/s12879-017-2750-9.","DOI":"10.1186\/s12879-017-2750-9"},{"key":"11295_CR8","doi-asserted-by":"crossref","unstructured":"Mvelase NR, Singh R, Swe Swe-Han K, Mlisana KP. Pyrazinamide resistance in rifampicin discordant tuberculosis. PLOS ONE. 2022;17(9):e0274688.","DOI":"10.1371\/journal.pone.0274688"},{"issue":"4","key":"11295_CR9","doi-asserted-by":"publisher","first-page":"277","DOI":"10.12701\/yujm.2020.00626","volume":"37","author":"JG Jang","year":"2020","unstructured":"Jang JG, Chung JH. Diagnosis and treatment of multidrug-resistant tuberculosis. Yeungnam Univ J Med. 2020;37(4):277\u201385.","journal-title":"Yeungnam Univ J Med"},{"issue":"1","key":"11295_CR10","doi-asserted-by":"publisher","first-page":"20","DOI":"10.37899\/journallamedihealtico.v4i1.793","volume":"4","author":"B Talarima","year":"2023","unstructured":"Talarima B. Duration of contact on pulmonary Tb transmission: case study-control. J La Medihealtico. 2023;4(1):20\u20138.","journal-title":"J La Medihealtico"},{"key":"11295_CR11","doi-asserted-by":"publisher","first-page":"1014666","DOI":"10.1155\/2023\/1014666","volume":"2023","author":"OM Craciun","year":"2023","unstructured":"Craciun OM, Torres MDR, Llanes AB, Romay-Barja M. Tuberculosis knowledge, attitudes, and practice in middle- and low-income countries: a systematic review. J Trop Med. 2023;2023:1014666.","journal-title":"J Trop Med"},{"key":"11295_CR12","unstructured":"Treatment regimens for drug resistant TB will see a price drop up to 29% [press release]. Geneva: STOP TB Partnership; 2023."},{"issue":"6","key":"11295_CR13","doi-asserted-by":"publisher","first-page":"315","DOI":"10.3390\/tropicalmed8060315","volume":"8","author":"LM Faye","year":"2023","unstructured":"Faye LM, Hosu MC, Iruedo J, Vasaikar S, Nokoyo KA, Tsuro U, et al. Treatment outcomes and associated factors among tuberculosis patients from selected rural eastern cape hospitals: an ambidirectional study. Trop Med Infect Dis. 2023;8(6):315.","journal-title":"Trop Med Infect Dis."},{"key":"11295_CR14","first-page":"Ch. 8","volume-title":"Healthcare Access","author":"San L Kyaw","year":"2019","unstructured":"Kyaw San L. Loss to Follow-Up (LTFU) during tuberculosis treatment. In: Umar B, Ur\u0161ka R, Sonja \u0160ostar T, editors. Healthcare Access. Rijeka: IntechOpen; 2019. p. Ch. 8."},{"key":"11295_CR15","doi-asserted-by":"publisher","unstructured":"Okethwangu D, Birungi D, Biribawa C, Kwesiga B, Turyahabwe S, Ario AR, Zhu BP. Multidrug-resistant tuberculosis outbreak associated with poor treatment adherence and delayed treatment: Arua District, Uganda, 2013-2017. BMC Infect Dis. 2019;19(1):387. https:\/\/doi.org\/10.1186\/s12879-019-4014-3. PMID: 31064332; PMCID: PMC6503550.","DOI":"10.1186\/s12879-019-4014-3"},{"key":"11295_CR16","doi-asserted-by":"crossref","unstructured":"Shewade1 HD, AMK, ARS, MV, MP, Chauhan A, et al. High pre-diagnosis attrition among patients with presumptive MDR-TB: an operational research from Bhopal district, India. 2017.","DOI":"10.1186\/s12913-017-2191-6"},{"issue":"4","key":"11295_CR17","doi-asserted-by":"publisher","first-page":"e0214943","DOI":"10.1371\/journal.pone.0214943","volume":"14","author":"C Xu","year":"2019","unstructured":"Xu C, Li R, Shewade HD, Jeyashree K, Ruan Y, Zhang C, et al. Attrition and delays before treatment initiation among patients with MDR-TB in China (2006\u201313): Magnitude and risk factors. PLoS One. 2019;14(4):e0214943.","journal-title":"PLoS One"},{"issue":"3","key":"11295_CR18","doi-asserted-by":"publisher","first-page":"e0248687","DOI":"10.1371\/journal.pone.0248687","volume":"16","author":"A Andargie","year":"2021","unstructured":"Andargie A, Molla A, Tadese F, Zewdie S. Lost to follow-up and associated factors among patients with drug resistant tuberculosis in Ethiopia: a systematic review and meta-analysis. PLoS One. 2021;16(3):e0248687.","journal-title":"PLoS One"},{"issue":"8","key":"11295_CR19","first-page":"6","volume":"6","author":"S Ghildiyal","year":"2022","unstructured":"Ghildiyal S, Sharma P, Rodrigues R, Arora MK. Pre-treatment loss to follow-up during course of tuberculosis: a systematic review. J Posit Sch Psychol. 2022;6(8):6.","journal-title":"J Posit Sch Psychol"},{"key":"11295_CR20","unstructured":"TREATTB. STREAM trial 2020. Available from: https:\/\/treattb.org\/trial-sites\/uganda\/."},{"key":"11295_CR21","unstructured":"WHO. World Health Organisation conducts mid-term review of Uganda\u2019s response to TB 2023 [updated 07 June 2023]. 2023. Available from: https:\/\/www.afro.who.int\/countries\/uganda\/news\/who-conducts-mid-term-review-ugandas-response-tb."},{"key":"11295_CR22","unstructured":"Kamara V. Improving treatment adherence for multi-drug resistant tuberculosis in Uganda using DHIS2. DHSI2; 2020. Available from: https:\/\/dhis2.org\/uganda-tb-tracker\/#:~:text=Two%20out%20of%20every%20100,complete%20their%20treatment%20as%20prescribed."},{"key":"11295_CR23","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.2147\/IDR.S300585","volume":"14","author":"TA Demissie","year":"2021","unstructured":"Demissie TA, Belayneh D. Magnitude of Mycobacterium tuberculosis infection and its resistance to rifampicin using Xpert-MTB\/RIF assay among presumptive tuberculosis patients at Motta General Hospital, Northwest Ethiopia. Infect Drug Resist. 2021;14:1335\u201341.","journal-title":"Infect Drug Resist"},{"issue":"1","key":"11295_CR24","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1186\/s12879-020-04982-z","volume":"20","author":"S Glasauer","year":"2020","unstructured":"Glasauer S, Kr\u00f6ger S, Haas W, Perumal N. International tuberculosis contact-tracing notifications in Germany: analysis of national data from 2010 to 2018 and implications for efficiency. BMC Infect Dis. 2020;20(1):267.","journal-title":"BMC Infect Dis"},{"issue":"1","key":"11295_CR25","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1186\/s12890-021-01735-9","volume":"21","author":"S Soedarsono","year":"2021","unstructured":"Soedarsono S, Mertaniasih NM, Kusmiati T, Permatasari A, Juliasih NN, Hadi C, et al. Determinant factors for loss to follow-up in drug-resistant tuberculosis patients: the importance of psycho-social and economic aspects. BMC Pulm Med. 2021;21(1):360.","journal-title":"BMC Pulm Med"},{"issue":"5","key":"11295_CR26","doi-asserted-by":"publisher","first-page":"3102","DOI":"10.21037\/jtd.2018.05.11","volume":"10","author":"A Esmail","year":"2018","unstructured":"Esmail A, Sabur NF, Okpechi I, Dheda K. Management of drug-resistant tuberculosis in special sub-populations including those with HIV co-infection, pregnancy, diabetes, organ-specific dysfunction, and in the critically ill. J Thorac Dis. 2018;10(5):3102\u201318.","journal-title":"J Thorac Dis"},{"key":"11295_CR27","unstructured":"CDC. Division of Tuberculosis Elimination, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention. Center of Disease Control and Prevention; 2022. Available from: https:\/\/www.cdc.gov\/tb\/topic\/drtb\/default.htm. Updated October 13, 2022; cited 2022."},{"key":"11295_CR28","doi-asserted-by":"publisher","first-page":"905245","DOI":"10.3389\/fmed.2022.905245","volume":"9","author":"Y Xue","year":"2022","unstructured":"Xue Y, Zhou J, Wang P, Lan JH, Lian WQ, Fan YY, et al. Burden of tuberculosis and its association with socio-economic development status in 204 countries and territories, 1990\u20132019. Front Med. 2022;9:905245.","journal-title":"Front Med"},{"issue":"4","key":"11295_CR29","doi-asserted-by":"publisher","first-page":"e0215542","DOI":"10.1371\/journal.pone.0215542","volume":"14","author":"C Oga-Omenka","year":"2019","unstructured":"Oga-Omenka C, Zarowsky C, Agbaje A, Kuye J, Menzies D. Rates and timeliness of treatment initiation among drug-resistant tuberculosis patients in Nigeria- a retrospective cohort study. PLoS One. 2019;14(4):e0215542.","journal-title":"PLoS One"},{"issue":"12","key":"11295_CR30","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.3390\/ijerph21121594","volume":"21","author":"LM Faye","year":"2024","unstructured":"Faye LM, Hosu MC, Apalata T. Drug-resistant tuberculosis in rural Eastern Cape, South Africa: a study of patients\u2019 characteristics in selected healthcare facilities. Int J Environ Res Public Health. 2024;21(12):1594.","journal-title":"Int J Environ Res Public Health"},{"issue":"3","key":"11295_CR31","doi-asserted-by":"publisher","first-page":"e26434","DOI":"10.1002\/jia2.26434","volume":"28","author":"JL Ross","year":"2025","unstructured":"Ross JL, Rupasinghe D, Chanyachukul T, Crabtree Ram\u00edrez B, Murenzi G, Kwobah E, et al. Comorbidities and HIV-related factors associated with mental health symptoms and unhealthy substance use among older adults living with HIV in low- and middle-income countries: a cross-sectional study. J Int AIDS Soc. 2025;28(3):e26434.","journal-title":"J Int AIDS Soc"},{"issue":"4","key":"11295_CR32","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.4314\/ahs.v21i4.18","volume":"21","author":"C Ashaba","year":"2021","unstructured":"Ashaba C, Musoke D, Wafula ST, Konde-Lule J. Stigma among tuberculosis patients and associated factors in urban slum populations in Uganda. Afr Health Sci. 2021;21(4):1640\u201350.","journal-title":"Afr Health Sci"},{"issue":"Suppl 1","key":"11295_CR33","doi-asserted-by":"publisher","first-page":"S80","DOI":"10.5588\/pha.18.0096","volume":"9","author":"T Adepoyibi","year":"2019","unstructured":"Adepoyibi T, Keam T, Kuma A, Haihuie T, Hapolo M, Islam S, et al. A pilot model of patient education and counselling for drug-resistant tuberculosis in Daru, Papua New Guinea. Public Health Action. 2019;9(Suppl 1):S80\u20132.","journal-title":"Public Health Action"},{"key":"11295_CR34","doi-asserted-by":"publisher","first-page":"102057","DOI":"10.1016\/j.eclinm.2023.102057","volume":"61","author":"C Maynard","year":"2023","unstructured":"Maynard C, Tariq S, Sotgiu G, Migliori GB, van den Boom M, Field N. Psychosocial support interventions to improve treatment outcomes for people living with tuberculosis: a mixed methods systematic review and meta-analysis. eClinicalMedicine. 2023;61:102057.","journal-title":"eClinicalMedicine"},{"key":"11295_CR35","unstructured":"WHO. World Health Organisation extends support towards tuberculosis diagnosis in Uganda. WHO extends support towards tuberculosis diagnosis in Uganda. 2019. Available from: https:\/\/www.afro.who.int\/news\/who-extends-support-towards-tuberculosis-diagnosis-uganda."},{"issue":"1","key":"11295_CR36","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1186\/s12879-021-06675-7","volume":"21","author":"BN Simbwa","year":"2021","unstructured":"Simbwa BN, Katamba A, Katana EB, Laker EAO, Nabatanzi S, Sendaula E, et al. The burden of drug resistant tuberculosis in a predominantly nomadic population in Uganda: a mixed methods study. BMC Infect Dis. 2021;21(1):950.","journal-title":"BMC Infect Dis"},{"issue":"1","key":"11295_CR37","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/s12879-018-3039-3","volume":"18","author":"BE Thomas","year":"2018","unstructured":"Thomas BE, Subbaraman R, Sellappan S, Suresh C, Lavanya J, Lincy S, et al. Pretreatment loss to follow-up of tuberculosis patients in Chennai, India: a cohort study with implications for health systems strengthening. BMC Infect Dis. 2018;18(1):142.","journal-title":"BMC Infect Dis"},{"key":"11295_CR38","unstructured":"WHO. World Health Organisation; Framework for implementing the \u201cend TB strategy\u201d in the African region 2016\u2013 2020. World Health Organization Regional Office for Africa; 2017. Available from: https:\/\/iris.who.int\/bitstream\/handle\/10665\/259636\/TBstrat-eng.pdf."},{"key":"11295_CR39","doi-asserted-by":"publisher","unstructured":"MacPherson P, Houben RM, Glynn JR, Corbett EL, Kranzer K. Pre-treatment loss to follow-up in tuberculosis patients in low- and lower-middle-income countries and high-burden countries: a systematic review and meta-analysis. Bull World Health Organ. 2014;92(2):126\u201338. https:\/\/doi.org\/10.2471\/BLT.13.124800. Epub 2013 Nov 22. PMID: 24623906; PMCID: PMC3949536.","DOI":"10.2471\/BLT.13.124800"},{"key":"11295_CR40","doi-asserted-by":"crossref","unstructured":"Kakame KT, Namuhani N, Kazibwe A, et al. Missed opportunities in tuberculosis investigation and associated factors at public health facilities in Uganda. BMC Health Serv Res. 2021;21:359. https:\/\/doi.org\/10.1186\/s12913-021-06368-6.","DOI":"10.1186\/s12913-021-06368-6"},{"key":"11295_CR41","volume-title":"Ministry of Health, annual report (July 2022-June 2023, TB league table","author":"MoH","year":"2024","unstructured":"MoH. Ministry of Health, annual report (July 2022-June 2023, TB league table. Kampala: Uganda Ministry of Health; 2024."},{"key":"11295_CR42","doi-asserted-by":"publisher","first-page":"7029458","DOI":"10.1155\/2020\/7029458","volume":"2020","author":"M Abayneh","year":"2020","unstructured":"Abayneh M, HaileMariam S, Asres A. Low tuberculosis (TB) case detection: a health facility-based study of possible obstacles in Kaffa Zone, Southwest District of Ethiopia. Can J Infect Dis Med Microbiol. 2020;2020:7029458.","journal-title":"Can J Infect Dis Med Microbiol"},{"issue":"1","key":"11295_CR43","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1186\/s12913-024-12115-4","volume":"24","author":"R Nuwematsiko","year":"2024","unstructured":"Nuwematsiko R, Kiwanuka N, Wafula ST, Nakafeero M, Nakanjako L, Luzze H, et al. Pre-diagnosis and pre-treatment loss to follow-up and associated factors among patients with presumed tuberculosis and those diagnosed in Uganda. BMC Health Serv Res. 2024;24(1):1638.","journal-title":"BMC Health Serv Res"},{"key":"11295_CR44","unstructured":"Jones E, Boyce E, Stine J. The role of health departments in advancing a new community health and wellness agenda. Prev Chronic Dis. 2007;4(3):A48."},{"issue":"1","key":"11295_CR45","doi-asserted-by":"publisher","first-page":"2148355","DOI":"10.1080\/16549716.2022.2148355","volume":"16","author":"MN Mulaku","year":"2023","unstructured":"Mulaku MN, Nyagol B, Owino EJ, Ochodo E, Young T, Steingart KR. Factors contributing to pre-treatment loss to follow-up in adults with pulmonary tuberculosis: a qualitative evidence synthesis of patient and healthcare worker perspectives. Glob Health Action. 2023;16(1):2148355.","journal-title":"Glob Health Action."},{"key":"11295_CR46","unstructured":"Organization WH. Definitions and reporting framework for tuberculosis\u20132013 revision: updatedDecember 2014 and January 2020. Definitions and reporting framework for tuberculosis\u20132013 revision:updated December 2014 and January 2020. 2020"},{"key":"11295_CR47","unstructured":"WHO. Prevention, care and treatment of viral hepatitis in the African region: framework for action, 2016\u2013 2020. World Health Organisation; 2017. Available from: https:\/\/www.afro.who.int\/sites\/default\/files\/2017-12\/HEPATITIS%20in%20Africa%20WHO%20African%20Region%202016-2020%20FINAL%20%2029%20Nov_FA_ENGLISH_WEB.pdf."},{"issue":"4","key":"11295_CR48","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1136\/oem.55.4.272","volume":"55","author":"ML Thompson","year":"1998","unstructured":"Thompson ML, Myers JE, Kriebel D. Prevalence odds ratio or prevalence ratio in the analysis of cross sectional data: what is to be done? Occup Environ Med. 1998;55(4):272.","journal-title":"Occup Environ Med"},{"key":"11295_CR49","unstructured":"MoH. Ministry of Health, Uganda national strategic plan for tuberculosis and leprosy control 2020\/21\u2013 2024\/25. Kampala; 2020."},{"key":"11295_CR50","unstructured":"Oyediran K, Kirenga B, Turyahabwe S, Davis N, Chauffour J, Muttamba W, Muzoora A, Muyinda H.\u00a0Quality of Tuberculosis Services Assessment in Uganda. 2020. Available from: https:\/\/www.measureevaluation.org\/resources\/publications\/tr-20-398.html."},{"key":"11295_CR51","doi-asserted-by":"crossref","unstructured":"Zawedde-Muyanja S, Katamba A, Cattamanchi A, Castelnuovo B, Manabe CY. Patient and health system factors associated with pretreatment loss to follow up among patients diagnosed with tuberculosis using Xpert MTB\/RIF testing in Uganda. 2020.","DOI":"10.21203\/rs.2.17693\/v3"},{"issue":"4","key":"11295_CR52","doi-asserted-by":"publisher","first-page":"148","DOI":"10.5588\/pha.22.0051","volume":"12","author":"S Daka","year":"2022","unstructured":"Daka S, Matsuoka Y, Ota M, Hirao S, Phiri A. Causes of pre-treatment loss to follow-up in patients with TB. Public Health Action. 2022;12(4):148\u201352.","journal-title":"Public Health Action"},{"key":"11295_CR53","doi-asserted-by":"crossref","unstructured":"Kurd SA, Wali A, Fatima R, Yaqoob A, Khan D, Lehri1 S. Pre-treatment loss to follow-up among patients with rifampicin-resistant tuberculosis in Baluchistan, Pakistan, 2012\u201317: a retrospective cohort study [version 1; peer review: 1 approved with reservations, 1 not approved]. 2018.","DOI":"10.12688\/f1000research.17057.1"},{"key":"11295_CR54","doi-asserted-by":"publisher","unstructured":"Shewade HD, Kokane AM, Singh AR, et al. High pre-diagnosis attrition among patients with presumptive MDR-TB: an operational research from Bhopal district, India. BMC Health Serv Res. 2017;17:249.\u00a0https:\/\/doi.org\/10.1186\/s12913-017-2191-6.","DOI":"10.1186\/s12913-017-2191-6"},{"key":"11295_CR55","doi-asserted-by":"publisher","unstructured":"Buregyeya E, Kasasa S, Mitchell EMH. Tuberculosis infection control knowledge and attitudes among health workers in Uganda: a cross-sectional study. BMC Infect Dis. 2016;16:416. https:\/\/doi.org\/10.1186\/s12879-016-1740-7.","DOI":"10.1186\/s12879-016-1740-7"},{"key":"11295_CR56","doi-asserted-by":"publisher","first-page":"1136094","DOI":"10.3389\/fmed.2023.1136094","volume":"10","author":"Y Jiang","year":"2023","unstructured":"Jiang Y, Chen J, Ying M, Liu L, Li M, Lu S, et al. Factors associated with loss to follow-up before and after treatment initiation among patients with tuberculosis: a 5-year observation in China. Front Med. 2023;10:1136094.","journal-title":"Front Med"},{"issue":"3","key":"11295_CR57","doi-asserted-by":"publisher","first-page":"491","DOI":"10.3201\/eid2203.151788","volume":"22","author":"TE Tupasi","year":"2016","unstructured":"Tupasi TE, Garfin AM, Kurbatova EV, Mangan JM, Orillaza-Chi R, Naval LC, et al. Factors Associated with loss to follow-up during treatment for multidrug-resistant tuberculosis, the Philippines, 2012\u20132014. Emerg Infect Dis. 2016;22(3):491\u2013502.","journal-title":"Emerg Infect Dis"},{"key":"11295_CR58","doi-asserted-by":"publisher","unstructured":"Birhane M, Mekonnen S, Dingeta T, Teklemariam Z. Loss to follow-up tuberculosis treatment and associated factors among adults attending at public health facilities in Warder District, Somali Regional State, Eastern Ethiopia. Front Public Health. 2023;11:1151077. https:\/\/doi.org\/10.3389\/fpubh.2023.1151077. PMID: 37234759; PMCID: PMC10208408.","DOI":"10.3389\/fpubh.2023.1151077"},{"issue":"1","key":"11295_CR59","first-page":"1","volume":"44","author":"HH Tola","year":"2015","unstructured":"Tola HH, Tol A, Shojaeizadeh D, Garmaroudi G. Tuberculosis treatment non-adherence and lost to follow up among TB patients with or without HIV in developing countries: a systematic review. Iran J Public Health. 2015;44(1):1\u201311.","journal-title":"Iran J Public Health"},{"issue":"8","key":"11295_CR60","doi-asserted-by":"publisher","first-page":"e0135802","DOI":"10.1371\/journal.pone.0135802","volume":"10","author":"RD Deshmukh","year":"2015","unstructured":"Deshmukh RD, Dhande DJ, Sachdeva KS, Sreenivas A, Kumar AM, Satyanarayana S, et al. Patient and provider reported reasons for lost to follow up in MDRTB treatment: a qualitative study from a drug resistant TB Centre in India. PLoS One. 2015;10(8):e0135802.","journal-title":"PLoS One"},{"issue":"2","key":"11295_CR61","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.pneumo.2016.11.001","volume":"73","author":"EL Bemba","year":"2017","unstructured":"Bemba EL, Bopaka RG, Ossibi-Ibara R, Toungou SN, Ossale-Abacka BK, Okemba-Okombi FH, et al. Predictive factors of lost to follow-up status during tuberculosis treatment in Brazzaville. Rev Pneumol Clin. 2017;73(2):81\u20139.","journal-title":"Rev Pneumol Clin"},{"issue":"Suppl 2","key":"11295_CR62","doi-asserted-by":"publisher","first-page":"S41","DOI":"10.5588\/pha.14.0048","volume":"4","author":"G Kuchukhidze","year":"2014","unstructured":"Kuchukhidze G, Kumar AM, de Colombani P, Khogali M, Nanava U, Blumberg HM, et al. Risk factors associated with loss to follow-up among multidrug-resistant tuberculosis patients in Georgia. Public Health Action. 2014;4(Suppl 2):S41\u20136.","journal-title":"Public Health Action"},{"issue":"5","key":"11295_CR63","first-page":"714","volume":"18","author":"AS Belchior","year":"2016","unstructured":"Belchior AS, Mainbourg EMT, Ferreira-Gon\u00e7alves MJ. Loss to follow-up in tuberculosis treatment and its relationship with patients\u2019 knowledge of the disease and other associated factors. Rev Salud Publica. 2016;18(5):714\u201326.","journal-title":"Rev Salud Publica"},{"issue":"6","key":"11295_CR64","doi-asserted-by":"publisher","first-page":"786","DOI":"10.5588\/ijtld.15.0895","volume":"20","author":"M Jensenius","year":"2016","unstructured":"Jensenius M, Winje BA, Blomberg B, Mengshoel AT, Lippe B, Hannula R, et al. Multidrug-resistant tuberculosis in Norway: a nationwide study, 1995\u20132014. Int J Tuberc Lung Dis. 2016;20(6):786\u201392.","journal-title":"Int J Tuberc Lung Dis"},{"issue":"3","key":"11295_CR65","doi-asserted-by":"publisher","first-page":"237","DOI":"10.5588\/pha.17.0044","volume":"7","author":"J Scuffell","year":"2017","unstructured":"Scuffell J, Boccia D, Garcia Velarde F, Leon SR, Raviola G, Lecca L, et al. Mental disorders and drug\/alcohol use in patients commencing extensively drug-resistant tuberculosis treatment. Public Health Action. 2017;7(3):237\u20139.","journal-title":"Public Health Action"},{"issue":"12","key":"11295_CR66","doi-asserted-by":"publisher","first-page":"e0261152","DOI":"10.1371\/journal.pone.0261152","volume":"16","author":"P Mishra","year":"2021","unstructured":"Mishra P, Sharma RK, Yadav R, Rao VG, Nigam S, Lingala MA, et al. Reasons for loss to follow-up (LTFU) of pulmonary TB (PTB) patients: a qualitative study among Saharia, a particularly vulnerable tribal group of Madhya Pradesh, India. PLoS One. 2021;16(12):e0261152.","journal-title":"PLoS One"},{"key":"11295_CR67","doi-asserted-by":"crossref","unstructured":"Rintiswati N, Mahendradhata Y, Suharna, Susilawati, Purwanta, Subronto Y, et al. Journeys to tuberculosis treatment: a qualitative study of patients, families and communities in Jogjakarta, Indonesia. BMC Public Health. 2009;9(1):158.","DOI":"10.1186\/1471-2458-9-158"},{"key":"11295_CR68","doi-asserted-by":"publisher","unstructured":"Mburu G, Ayon S, Tsai AC, et al. \u201cWho has ever loved a drug addict? It\u2019s a lie. They think a \u2018teja\u2019 is as bad person\u201d: multiple stigmas faced by women who inject drugs in coastal Kenya. Harm Reduct J. 2018;15:29.\u00a0https:\/\/doi.org\/10.1186\/s12954-018-0235-9.","DOI":"10.1186\/s12954-018-0235-9"},{"issue":"1","key":"11295_CR69","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s41043-017-0132-y","volume":"37","author":"FH Gebreweld","year":"2018","unstructured":"Gebreweld FH, Kifle MM, Gebremicheal FE, Simel LL, Gezae MM, Ghebreyesus SS, et al. Factors influencing adherence to tuberculosis treatment in Asmara, Eritrea: a qualitative study. J Health Popul Nutr. 2018;37(1):1.","journal-title":"J Health Popul Nutr"},{"issue":"3","key":"11295_CR70","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.4269\/ajtmh.19-0415","volume":"103","author":"TJ Zhou","year":"2020","unstructured":"Zhou TJ, Lakshminarayanan S, Sarkar S, Knudsen S, Horsburgh CR, Muthaiah M, et al. Predictors of loss to follow-up among men with tuberculosis in Puducherry and Tamil Nadu, India. Am J Trop Med Hyg. 2020;103(3):1050\u20136.","journal-title":"Am J Trop Med Hyg"},{"key":"11295_CR71","doi-asserted-by":"publisher","unstructured":"Ekuka G, Kawooya I, Kayongo E, Ssenyonga R, Mugabe F, Chaiga PA, Nsawotebba A, Tweya H, Mijumbi-Deve R. Pre-diagnostic drop out of presumptive TB patients and its associated factors at Bugembe Health Centre IV in Jinja, Uganda. Afr Health Sci. 2020;20(2):633\u201340. https:\/\/doi.org\/10.4314\/ahs.v20i2.11. PMID: 33163024; PMCID: PMC7609087.","DOI":"10.4314\/ahs.v20i2.11"},{"key":"11295_CR72","doi-asserted-by":"publisher","unstructured":"Becerra M C, Huang C, Lecca L, Bayona J, Contreras C, Calderon R et al. Transmissibility and potential for disease progression of drug resistant Mycobacterium tuberculosis: prospective cohort study. BMJ. 2019;367:l5894. https:\/\/doi.org\/10.1136\/bmj.l5894.","DOI":"10.1136\/bmj.l5894"},{"key":"11295_CR73","doi-asserted-by":"publisher","unstructured":"Ngabonziza JS, Habimana YM, Decroo T, Migambi P, Dushime A, Mazarati JB, Rigouts L, Affolabi D, Ivan E, Meehan CJ, Van Deun A, Fissette K, Habiyambere I, Nyaruhirira AU, Turate I, Semahore JM, Ndjeka N, Muvunyi CM, Condo JU, Gasana M, Hasker E, Torrea G, de Jong BC. Reduction of diagnostic and treatment delays reduces rifampicin-resistant tuberculosis mortality in Rwanda. Int J Tuberc Lung Dis. 2020;24(3):329\u201339. https:\/\/doi.org\/10.5588\/ijtld.19.0298. PMID: 32228764.","DOI":"10.5588\/ijtld.19.0298"},{"issue":"2","key":"11295_CR74","doi-asserted-by":"publisher","first-page":"ofw068","DOI":"10.1093\/ofid\/ofw068","volume":"3","author":"CF Hanrahan","year":"2016","unstructured":"Hanrahan CF, Haguma P, Ochom E, Kinera I, Cobelens F, Cattamanchi A, et al. Implementation of Xpert MTB\/RIF in Uganda: missed opportunities to improve diagnosis of tuberculosis. Open Forum Infect Dis. 2016;3(2):ofw068.","journal-title":"Open Forum Infect Dis"},{"key":"11295_CR75","doi-asserted-by":"publisher","unstructured":"Nalugwa T, Shete PB, Nantale M, Farr K, Ojok C, Ochom E, Mugabe F, Joloba M, Dowdy DW, Moore DAJ, Davis JL, Cattamanchi A, Katamba A. Challenges with scale-up of GeneXpert MTB\/RIF\u00ae in Uganda: a health systems perspective. BMC Health Serv Res. 2020;20(1):162. https:\/\/doi.org\/10.1186\/s12913-020-4997-x. PMID: 32131814; PMCID: PMC7057496.","DOI":"10.1186\/s12913-020-4997-x"},{"key":"11295_CR76","doi-asserted-by":"publisher","unstructured":"Joloba M, Mwangi C, Alexander H, Nadunga D, Bwanga F, Modi N, Downing R, Nabasirye A, Adatu FE, Shrivastava R, Gadde R, Nkengasong JN. Strengthening the Tuberculosis Specimen Referral Network in Uganda: The Role of Public-Private Partnerships. J Infect Dis. 2016;213 Suppl 2(Suppl 2):S41\u20136. https:\/\/doi.org\/10.1093\/infdis\/jiw035. PMID: 27025697; PMCID: PMC4914746.","DOI":"10.1093\/infdis\/jiw035"},{"issue":"2","key":"11295_CR77","doi-asserted-by":"publisher","first-page":"128","DOI":"10.3402\/ijch.v70i2.17810","volume":"70","author":"P Orr","year":"2011","unstructured":"Orr P. Adherence to tuberculosis care in Canadian Aboriginal populations, part 2: a comprehensive approach to fostering adherent behaviour. Int J Circumpolar Health. 2011;70(2):128\u201340.","journal-title":"Int J Circumpolar Health"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-11295-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-025-11295-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-11295-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T10:50:26Z","timestamp":1757328626000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-025-11295-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,31]]},"references-count":77,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["11295"],"URL":"https:\/\/doi.org\/10.1186\/s12879-025-11295-6","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,31]]},"assertion":[{"value":"17 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki. The study was reviewed by Makerere University School of Public Health Research and Ethical Committee, located at the School of Public Health, Makerere University, which is an accredited Institutional Review Board (IRB) for approval (number MakSPH-REC 068). Permission was then sought from the Ministry of Health to access eCBSS platform; from the office of the District Health officer and the health facility in charge before the collection. The secondary data extracted was de-identified and assigned a decoy participant ID.Participants for KIIs and FGDs received information about the study objectives, procedures, and benefits; and asked to consent to participate in the study. Informed consent for participants interviewed was obtained before being interviewed. Privacy and confidentiality of data were ensured by masking participants with personal identifiers like name, and was addressed by assigning a unique code to each participant. Participants were free to accept or refuse to participate in the study. There was no anticipated harm to the participants during this study except for the time they gave in during data collection.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"967"}}